ASH Clinical News ACN_4.14_Full Issue_web | Page 106

A NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORY 1
PREFERRED REGIMEN FOR R/R CLL/SLL WITH OR WITHOUT 17p DELETION 1 *
NOW
APPROVED
VENCLEXTA (venetoclax tablets)
in combination with rituximab
®
for CLL/SLL patients with or without 17p deletion
who have received at least one prior therapy 2
Indication
• VENCLEXTA ® (venetoclax tablets) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
R/R=relapsed/refractory.
* See NCCN Guidelines for the NCCN definitions of Categories
of Preference and Categories of Evidence and Consensus.
VENCLEXTA is a registered trademark of AbbVie, Inc.
Learn more at VENCLEXTAhcp.com
®
Distributed and marketed by AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064
Marketed by Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990
©2018 AbbVie, Inc. and Genentech USA, Inc. US-VNCCLL-180017/August 2018 Printed in USA